Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSeed Regulatory News (SEED)

Share Price Information for Seed (SEED)

Share Price is delayed by 15 minutes
Get Live Data
3.00    0.00 (0.00%)
Bid:
2.80
Ask:
3.20
Spread: 0.40 (14.286%)
Market Cap: £5.64m
SEED Live PriceLast checked at - London Stock Exchange

Intraday Seed Share Chart

Leap Gaming Update – Offer Declared Unconditional

11 Apr 2023 07:00

RNS Number : 6790V
Seed Innovations Limited
11 April 2023
 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 ('MAR').

 

Seed Innovations Ltd / AIM: SEED / Sector: Closed End Investments

11 April 2023

SEED Innovations Ltd ("SEED" or, the "Company")

 

 Leap Gaming Update - Offer Declared Unconditional

Divestment will secure approximately €5.8m Cash to the Company over 2 year period

 

SEED Innovations Ltd, the AIM quoted company focusing on making investments in fast growing and industry leading businesses with a focus on the medical cannabis, health and wellness space, is pleased to announce that, further to the announcement of 7 December 2022, the sale of portfolio company Fralis LLC (trading as Leap Gaming, 'Leap'), is now unconditional and completion has occurred ('Completion').

 

As previously announced, Leap entered into a conditional Sale & Purchase Agreement ('SPA') for the sale of the remainder of Leap to existing unitholder IMG Arena US, LLC ('IMG') based upon an enterprise value of €14 million (the 'Leap Transaction'). IMG is an existing investor in, and was the second largest owner of, Leap. Following the transaction, Leap will be wholly owned by IMG.

 

Sale proceeds due to SEED will be received by the Company in the coming days as follows:

 

· €2.8 million being 50% of the sale proceeds due to SEED under the agreement (and after adjustment for working capital and repayment of debt); and

 

· €268,000 being repayment of the Company's €250,000 term loan (as announced on 8 June 2022), together with accrued interest.

 

The second tranche of sale proceeds, being €2.8 million (calculated as the remaining 50% of the sale proceeds and subject only to any claims under customary warranties & indemnities,), is expected to be received in April 2024, being the 12-month anniversary of Completion, as per the terms of the SPA.

 

The Company intends to use the proceeds received for making further investments in accordance with its investing policy.

 

Ed McDermott, CEO, commented: "I am pleased to be able to confirm to shareholders that the sale of Leap to IMG Arena has been declared unconditional and has concluded in line with the anticipated timelines. The initial cash proceeds, and the balance paid on the 12-month anniversary of Completion, provides us with liquidity at a time where we are seeing some very promising investment opportunities. We strongly believe that our portfolio has the potential to create short, medium- and long-term value creation. 

 

"We wish Leap and IMG well in the future."

 

 

ENDS

 

For further information on the Company please visit www.seedinnovations.co or contact:

 

Ed McDermott /

Lance de Jersey

SEED Innovations Ltd

E: info@seedinnovations.co

 

James Biddle /

Roland Cornish

Beaumont Cornish Limited,

Nomad

 

T: +44 (0) 207 628 3396

Isabella Pierre /

Damon Heath

Shard Capital Partners LLP

 

T: +44 (0)20 7186 9927

Catherine Leftley /Isabelle Morris/

Max Bennett

St Brides Partners Ltd,

Financial PR

 

E: info@stbridespartners.co.uk

 

Notes

SEED Innovations is an AIM quoted investment company focused primarily on disruptive high growth life sciences and technology businesses particularly within the medical cannabis arena. The Company's strategy is to identify early-stage opportunities that have an upcoming investment catalyst and grow its portfolio in terms of value whilst limiting the number of investee companies to a level where relevant time can be devoted to each.

 

Leap is a developer of high-end virtual-sports, slots, and casino applications serving hundreds of gaming brands and generating tens of thousands of engagement points with end-users. Leap's attention to detail in its solutions and services is manifested in the modular engagement terms it offers to its operating partners and its ability to provide seamless experiences across mobile, desktop and retail environments. Leap is licensed by the MGA and certified for other jurisdictions worldwide, including the United Kingdom, Sweden, the Netherlands, Romania, South Africa and Greece.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDEADLKESLDEFA
Date   Source Headline
7th May 20267:00 amRNSInvestment in Feather Robotics, Inc.
1st May 20267:00 amRNS-RInvestee Company Update: Little Green Pharma
15th Apr 20267:00 amRNS-RInvestor Presentation
14th Apr 20267:00 amRNSInvestment in Clean Food Group Funding Round
23rd Feb 20262:47 pmRNS-RInvestor Presentation Update
11th Feb 20267:00 amRNS-RInvestor Presentation
14th Jan 20262:46 pmRNSInvestee Company Update: Little Green Pharma
9th Jan 20263:19 pmRNSDirector's Dealing
23rd Dec 20257:00 amRNSAppointment of Specialist Investment Consultant
23rd Dec 20257:00 amRNSAppointment of Specialist Investment Consultant
10th Dec 202510:49 amRNS-RInvestor Presentation Postponed
8th Dec 20252:30 pmRNS-RIntroduction to Newly Appointed Directors
4th Dec 20257:00 amRNSInterim Results
26th Nov 20257:00 amRNSBoard Appointments
13th Nov 202510:07 amRNS-RInvestee Company Update: Little Green Pharma Ltd
25th Sep 20257:00 amRNS-RInvestee Company Update: Clean Food Group
18th Sep 20257:00 amRNSHolding(s) in Company
11th Sep 20257:00 amRNSHolding(s) in Company
10th Sep 20259:11 amRNSHolding(s) in Company
8th Sep 202511:01 amRNSResult of Tender Offer
14th Aug 20257:00 amRNSDirectorship Changes
14th Aug 20257:00 amRNSTender Offer
13th Aug 20253:09 pmRNSResult of AGM
5th Aug 20251:39 pmRNSHolding(s) in Company
1st Aug 202510:55 amRNSHolding(s) in Company
18th Jul 20257:00 amRNSNotice of AGM & Publication of Circular
18th Jul 20257:00 amRNSInvestee Company Update: Little Green Pharma Ltd
17th Jul 20257:00 amRNSDivestment of Oxford BioDynamics Position
20th Jun 20257:00 amRNSFinal Results
30th May 20252:33 pmRNS-RInvestee Company Update: Little Green Pharma Ltd
28th May 20258:03 amRNSHolding(s) in Company
23rd May 20257:41 amRNSHolding(s) in Company
22nd May 20257:00 amRNSInvestee Company Update: Juvenescence Ltd
30th Apr 202512:13 pmRNSInvestee Company Update: Little Green Pharma Ltd
30th Apr 202510:48 amRNSHolding(s) in Company
17th Apr 20257:00 amRNSHolding(s) in Company
7th Apr 20251:35 pmRNSHolding(s) in Company
28th Mar 20257:00 amRNS-RNew Corporate Presentation
25th Feb 20253:08 pmRNSHolding(s) in Company
5th Feb 202510:44 amRNSInvestee Company Update: Little Green Pharma Ltd
31st Jan 20251:02 pmRNSHolding(s) in Company
31st Jan 202512:38 pmRNSInvestee Company Update: Little Green Pharma Ltd
16th Jan 20257:00 amRNS-R2025 New Year Statement
20th Dec 20242:19 pmRNS-RInvestee Company Update: Little Green Pharma Ltd
10th Dec 20247:07 amRNSHolding(s) in Company
3rd Dec 20247:00 amRNSHalf-year Report
11th Nov 202412:43 pmRNSPortfolio Update
17th Oct 202412:00 pmRNSInvestee Company Update: Little Green Pharma Ltd
8th Oct 20247:24 amRNSPortfolio Update
24th Sep 20247:00 amRNSAGM Statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.